Carol Suh

Carol Suh is one of our co-founders and has served as our Chief Operating Officer since January 2023. From January 2022 through January 2023, she served as our Senior Vice President, Strategy and from January 2020 through December 2021 served as our Vice President of Business Development. Ms. Suh has been a member of ARCH Venture Partners since August 2018 and became a Partner in July 2021. While at ARCH, she has been involved in company creation and helped build multiple companies across the fields of cell and gene therapy, neuroscience, oncology and immunology. Ms. Suh is a co-founder of Orbital Therapeutics since March 2022 and has served on its board of directors since August 2022. She has served on the board of directors of HI-Bio since August 2021 and the Metrodora Foundation since October 2021.

Prior to ARCH, Ms. Suh helped launch Magenta Therapeutics, a biotechnology company, in 2016 and served as Business Development and Corporate Strategy Associate from June 2017 to September 2017. Previously, she was a consultant at Trinity Partners from 2015 to 2016. Ms. Suh began her career in R&D with GlaxoSmithKline’s Regenerative Medicine group in 2014.

Ms. Suh holds an A.B. in Molecular and Cellular Biology from Harvard University, where she trained under Dr. David Scadden at the Harvard Stem Cell Institute, an M.Phil. from Yale University, where she was awarded the National Science Foundation Graduate Research Fellowship for her work in stem cell biology, and an M.B.A. from Stanford Graduate School of Business.